JP2007500217A - 同種異系細胞治療：ミラー効果 - Google Patents

同種異系細胞治療：ミラー効果 Download PDF

Info

Publication number
JP2007500217A
JP2007500217A JP2006532922A JP2006532922A JP2007500217A JP 2007500217 A JP2007500217 A JP 2007500217A JP 2006532922 A JP2006532922 A JP 2006532922A JP 2006532922 A JP2006532922 A JP 2006532922A JP 2007500217 A JP2007500217 A JP 2007500217A
Authority
JP
Japan
Prior art keywords
cells
allogeneic
host
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500217A5 (enExample
Inventor
マイケル ハル−ノイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33425748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007500217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2007500217A publication Critical patent/JP2007500217A/ja
Publication of JP2007500217A5 publication Critical patent/JP2007500217A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2006532922A 2003-05-13 2004-05-11 同種異系細胞治療：ミラー効果 Pending JP2007500217A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47017103P 2003-05-13 2003-05-13
US54545004P 2004-02-18 2004-02-18
US54796604P 2004-02-26 2004-02-26
US54903204P 2004-03-01 2004-03-01
US10/838,454 US7435592B2 (en) 2003-05-13 2004-05-04 Compositions for allogeneic cell therapy
PCT/US2004/014589 WO2005001074A1 (en) 2003-05-13 2004-05-11 Allogeneic cell therapy: mirror effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010232031A Division JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果

Publications (2)

Publication Number Publication Date
JP2007500217A true JP2007500217A (ja) 2007-01-11
JP2007500217A5 JP2007500217A5 (enExample) 2010-12-02

Family

ID=33425748

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006532922A Pending JP2007500217A (ja) 2003-05-13 2004-05-11 同種異系細胞治療：ミラー効果
JP2010232031A Expired - Lifetime JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果
JP2011157205A Withdrawn JP2011225602A (ja) 2003-05-13 2011-07-15 同種異系細胞治療：ミラー効果
JP2014207763A Withdrawn JP2015028072A (ja) 2003-05-13 2014-10-09 同種異系細胞治療：ミラー効果
JP2016152801A Pending JP2016190868A (ja) 2003-05-13 2016-08-03 同種異系細胞治療：ミラー効果

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010232031A Expired - Lifetime JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果
JP2011157205A Withdrawn JP2011225602A (ja) 2003-05-13 2011-07-15 同種異系細胞治療：ミラー効果
JP2014207763A Withdrawn JP2015028072A (ja) 2003-05-13 2014-10-09 同種異系細胞治療：ミラー効果
JP2016152801A Pending JP2016190868A (ja) 2003-05-13 2016-08-03 同種異系細胞治療：ミラー効果

Country Status (6)

Country Link
US (15) US7435592B2 (enExample)
EP (1) EP1627054A1 (enExample)
JP (5) JP2007500217A (enExample)
CA (1) CA2525596C (enExample)
IL (4) IL171850A (enExample)
WO (1) WO2005001074A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
JP2007526314A (ja) * 2004-03-01 2007-09-13 イミュノバティブ セラピーズ， リミテッド 細胞治療処方方法および組成物
JP2011519869A (ja) * 2008-05-02 2011-07-14 イミュノバティブ セラピーズ， リミテッド ワクチン組成物および方法
JP2013514365A (ja) * 2009-12-15 2013-04-25 イミュノバティブ セラピーズ， リミテッド 腫瘍の一掃のための方法および組成物
JP2013523886A (ja) * 2010-04-13 2013-06-17 イミュノバティブ セラピーズ， リミテッド 制御性ｔ細胞の阻害のための方法および組成物
JP2013536232A (ja) * 2010-08-20 2013-09-19 イミュノバティブ セラピーズ， リミテッド Ｔｈ１特性と細胞溶解性を発現する細胞
JP2014513126A (ja) * 2011-05-03 2014-05-29 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
JP2014517830A (ja) * 2011-05-03 2014-07-24 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
JP2018108091A (ja) * 2011-04-08 2018-07-12 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
JP2022524146A (ja) * 2019-03-08 2022-04-27 ソプ シン，ジ 他家免疫細胞培養方法、その方法により得られた免疫細胞培養液、及びこれを含む免疫細胞治療剤
JP2022528079A (ja) * 2019-03-27 2022-06-08 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20070025961A1 (en) 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US8865224B2 (en) * 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
GB0622400D0 (en) * 2006-11-10 2006-12-20 Avaris Ab Novel compositions and uses thereof
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US9320794B2 (en) 2006-11-13 2016-04-26 Immunovative Therapies, Ltd. Ablative immunotherapy
US20090232032A1 (en) * 2007-01-17 2009-09-17 Verbal World, Inc. Methods and Apparatus for the Manipulation of Conferenced Data
US20100325229A1 (en) * 2008-02-08 2010-12-23 Verbal World, Inc. Methods and Apparatus for Exchange of Electronic Communications
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
JP5725489B2 (ja) * 2008-06-27 2015-05-27 公立大学法人大阪市立大学 医療用組成物および医療用キット
WO2010059253A2 (en) * 2008-11-24 2010-05-27 Massachusets Institute Of Technology Methods and compositions for localized agent delivery
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
EP2566954B2 (en) * 2010-05-04 2022-11-02 Yeda Research and Development Co. Ltd. Immunotherapy using redirected allogeneic cells
EP2595637B1 (en) * 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect
AU2011287108B2 (en) * 2010-08-06 2014-08-28 Canine-Lab.Inc. Immunological function enhancing agent
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
CN104906139B (zh) 2011-01-10 2020-10-23 小利兰·斯坦福大学托管委员会 异源造血干细胞移植的增强
RU2488356C1 (ru) * 2012-02-28 2013-07-27 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ коррекции иммунных нарушений
TWI676481B (zh) * 2012-05-02 2019-11-11 以色列商梵提夫免疫療法公司 使用免疫療法誘導ｉｌ－１２
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CA2782942C (en) * 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
CN102809596B (zh) * 2012-08-21 2014-07-09 辉源生物科技（上海）有限公司 分离培养新生鼠皮层神经细胞记录t型钙通道电流的方法
US20140065096A1 (en) * 2012-09-05 2014-03-06 Regen BioPharma, Inc. Cancer therapy by ex vivo activated autologous immune cells
EP3019176B1 (en) 2013-07-12 2020-05-06 Canadian Blood Services Use of acellular pro-inflammatory compositions and process for making same
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
CA2936086C (en) 2014-01-08 2024-02-27 Immunovative Therapies, Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
US10739353B2 (en) 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
AU2016305087B2 (en) 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
CA3100312A1 (en) 2018-05-14 2019-11-21 Regents Of The University Of Minnesota Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
WO2020032780A1 (ko) * 2018-08-10 2020-02-13 주식회사 유틸렉스 암항원 특이적 세포독성 t세포
US12605463B2 (en) 2019-04-12 2026-04-21 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
KR20230016178A (ko) 2020-04-15 2023-02-01 엘커메스 파마 아일랜드 리미티드 혈관신생 억제제와 조합된 면역자극제
WO2025221890A1 (en) * 2024-04-16 2025-10-23 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672895A (ja) * 1991-04-19 1994-03-15 Tanox Biosyst Inc 免疫調節能を有する物質及び組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
AU5729294A (en) 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US6143292A (en) * 1995-05-25 2000-11-07 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
EP0852618A1 (en) * 1995-07-25 1998-07-15 Celltherapy Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
IL126843A (en) 1996-05-23 2007-06-17 Scripps Research Inst Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro
CA2309206A1 (en) * 1997-11-10 1999-05-20 Arch Development Corporation Methods for treatment of tumors and tumor cells using ex vivo activated t cells
DE69841058D1 (de) 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen
ATE309808T1 (de) 1998-07-30 2005-12-15 Univ Minnesota Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US20020127208A1 (en) * 2000-08-31 2002-09-12 Waller Edmund K. Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
WO2003038062A2 (en) 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells
JP2004538331A (ja) * 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル インサイチュ免疫法
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP2007525225A (ja) 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
US8865224B2 (en) * 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
CA2649290C (en) 2006-04-13 2017-04-04 Immunovative Therapies, Ltd. Allogeneic cell therapy for treatment of opportunistic infection
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672895A (ja) * 1991-04-19 1994-03-15 Tanox Biosyst Inc 免疫調節能を有する物質及び組成物

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
JP2007526314A (ja) * 2004-03-01 2007-09-13 イミュノバティブ セラピーズ， リミテッド 細胞治療処方方法および組成物
JP2011519869A (ja) * 2008-05-02 2011-07-14 イミュノバティブ セラピーズ， リミテッド ワクチン組成物および方法
JP2016121164A (ja) * 2009-12-15 2016-07-07 イミュノバティブ セラピーズ，リミテッド 腫瘍の一掃のための方法および組成物
JP2013514365A (ja) * 2009-12-15 2013-04-25 イミュノバティブ セラピーズ， リミテッド 腫瘍の一掃のための方法および組成物
JP2018090605A (ja) * 2009-12-15 2018-06-14 イミュノバティブ セラピーズ，リミテッド 腫瘍の一掃のための方法および組成物
JP2013523886A (ja) * 2010-04-13 2013-06-17 イミュノバティブ セラピーズ， リミテッド 制御性ｔ細胞の阻害のための方法および組成物
JP2016155851A (ja) * 2010-04-13 2016-09-01 イミュノバティブ セラピーズ，リミテッド 制御性ｔ細胞の阻害のための方法および組成物
JP2017061558A (ja) * 2010-08-20 2017-03-30 イミュノバティブ セラピーズ，リミテッド Ｔｈ１特性と細胞溶解性を発現する細胞
JP2013536232A (ja) * 2010-08-20 2013-09-19 イミュノバティブ セラピーズ， リミテッド Ｔｈ１特性と細胞溶解性を発現する細胞
US10385315B2 (en) 2010-08-20 2019-08-20 Immunovative Therapies, Ltd. Cells expressing Th1 characteristics and cytolytic properties
JP2018108091A (ja) * 2011-04-08 2018-07-12 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
JP2014517830A (ja) * 2011-05-03 2014-07-24 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
JP2014513126A (ja) * 2011-05-03 2014-05-29 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
JP2017141287A (ja) * 2011-05-03 2017-08-17 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
US11045541B2 (en) 2011-05-03 2021-06-29 Mirror Biologics, Inc. Allogeneic T-cell compositions for induction of IL-12
US11883490B2 (en) 2011-05-03 2024-01-30 Mirror Biologics, Inc. Induction of IL-12 using immunotherapy
JP2022524146A (ja) * 2019-03-08 2022-04-27 ソプ シン，ジ 他家免疫細胞培養方法、その方法により得られた免疫細胞培養液、及びこれを含む免疫細胞治療剤
JP2022528079A (ja) * 2019-03-27 2022-06-08 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物
JP7335971B2 (ja) 2019-03-27 2023-08-30 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物

Also Published As

Publication number Publication date
US8298587B2 (en) 2012-10-30
US8778678B2 (en) 2014-07-15
US8785188B2 (en) 2014-07-22
US20110028912A1 (en) 2011-02-03
US9352001B2 (en) 2016-05-31
JP2011006491A (ja) 2011-01-13
US20110206707A1 (en) 2011-08-25
US20160158328A1 (en) 2016-06-09
US8679841B2 (en) 2014-03-25
EP1627054A1 (en) 2006-02-22
US20040228848A1 (en) 2004-11-18
US20080279836A1 (en) 2008-11-13
US20140294781A1 (en) 2014-10-02
IL171850A (en) 2014-02-27
US10806777B2 (en) 2020-10-20
JP2016190868A (ja) 2016-11-10
IL223010A0 (en) 2012-12-31
JP2011225602A (ja) 2011-11-10
US20110033435A1 (en) 2011-02-10
IL223011A0 (en) 2012-12-31
US20080279861A1 (en) 2008-11-13
CA2525596C (en) 2017-10-10
US9511127B2 (en) 2016-12-06
WO2005001074A1 (en) 2005-01-06
US8273377B2 (en) 2012-09-25
US9301977B2 (en) 2016-04-05
US20100322966A1 (en) 2010-12-23
US20140154278A1 (en) 2014-06-05
IL223009A0 (en) 2012-12-31
JP6030819B2 (ja) 2016-11-24
US7435592B2 (en) 2008-10-14
US8354276B2 (en) 2013-01-15
US9782463B2 (en) 2017-10-10
US20110040259A1 (en) 2011-02-17
CA2525596A1 (en) 2005-01-06
IL223011A (en) 2017-10-31
US7943180B2 (en) 2011-05-17
US8728534B2 (en) 2014-05-20
US20140193385A1 (en) 2014-07-10
US20130052212A1 (en) 2013-02-28
US20110206708A1 (en) 2011-08-25
US8076135B2 (en) 2011-12-13
JP2015028072A (ja) 2015-02-12
US20170360909A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
JP6030819B2 (ja) 同種異系細胞治療：ミラー効果
JP2007500217A5 (enExample)
US10385315B2 (en) Cells expressing Th1 characteristics and cytolytic properties
HK1257638A1 (en) Cells expressing th1 characteristics and cytolytic properties
HK1184498A (en) Cells expressing th1 characteristics and cytolytic properties
JPWO2005075628A1 (ja) 脱活性化ｂ１ｂ細胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100806

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329